Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Biotechnology

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.

Revenue projections:

Revenue projections for TECH
Revenue projections for TECH

With Bio-Techne Corporation's revenues forecasted to be lower than last year's, investors are expected to be cautious. A decline in revenue typically harms the company's bottom line, reducing profitability and making investors less confident about the company's ability to sustain its financial health.

Financial Ratios:

currentRatio 4.539000
forwardPE 25.451132
debtToEquity 17.449000
earningsGrowth 0.091000
revenueGrowth -0.004000
grossMargins 0.666050
operatingMargins 0.196700
trailingEps 0.530000
forwardEps 2.161790

TECH's current ratio, being 4.539, demonstrates that the company has the liquidity necessary to service its short-term debt. With strong cash reserves and current assets, TECH is well-equipped to meet its immediate financial obligations without any difficulties.
TECH's Forward PE ratio suggests the stock price is reasonable in relation to earnings. It's not overpriced, providing room for future growth, making the stock a potentially valuable investment for those seeking long-term gains.
TECH's low Debt-to-Equity ratio shows that the company avoids excessive reliance on debt, reducing financial risk. This suggests a more secure financial position with less vulnerability to debt-related risks, making TECH a stable and conservative investment.
Bio-Techne Corporation's low growth in earnings and revenue points to a likely reduction in profits. This signals a weakening financial performance, indicating the company might face difficulties in staying profitable.
Bio-Techne Corporation's negative gross and operating margins point to financial difficulties, as the company is unable to generate profit from its core operations or production. This could signal broader problems in cost management or declining sales.

Price projections:

Price projections for TECH
Price projections for TECH

Price projections for TECH have been gradually reduced, reflecting growing uncertainty about the company's future performance. The downward revisions indicate analysts are lowering their expectations for TECH's market trajectory.

Insider Transactions:

Insider Transactions for TECH
Insider Transactions for TECH


There were 3 transactions selling Bio-Techne Corporation stock, with prevailing market price of 55.03000005086263.There were no sell transactions recorded during the period under consideration.The higher volume of buys compared to sells near current TECH price levels may suggest optimism among investors. This could point to a favorable market outlook, as more people are willing to invest at these prices, anticipating potential future growth or strong performance.

Recommendation changes over time:

Recommendations trend for TECH
Recommendations trend for TECH


Analysts' buy bias toward Bio-Techne Corporation suggests the stock is seen as a solid investment, potentially motivating investors to consider it for their portfolios. With this positive outlook, Bio-Techne Corporation is likely to be viewed as a secure place to allocate funds, driving further interest in the stock.